|Articles|April 1, 1998

Clinical and Economic Considerations of Helicobacter pylori Eradication and Screening
Volume 4
Issue 5 Suppl

Evaluation of Outcomes Achieved Through Peptic Ulcer Disease State Management

Author(s)Edward J. Drea, PharmD

Download PDF: Evaluation of Outcomes Achieved Through Peptic Ulcer Disease State Management

Articles in this issue

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

The Impact of H Pylori Eradication on Your Pharmacy Budget

over 28 years ago

Article

Overview of H pylori in Peptic Ulcer Disease

over 28 years ago

Article

Clinical Issues and Cost Effectiveness of Treating H pylori

over 28 years ago

Article

Current Issues in H pylori Eradication

over 28 years ago

Article

Is Curing Peptic Ulcer Disease an Oxymoron? A Focus on Helicobacter pylori

over 28 years ago

Article

CPE Quiz

over 28 years ago

Article

Selected Abstracts

over 28 years ago

Article

Bibliography

over 28 years ago

Article

Efficacy and Economic Concerns Regarding H pylori Treatment in the Managed Care Setting

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Evaluation of Outcomes Achieved Through Peptic Ulcer Disease State Management

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

Medicaid MFN Pricing Could Save $8.6 Billion

Active US Drug Shortages Rise for Third Straight Quarter

Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

FAQs: FDA Lawsuit Challenges E-Cigarette Enforcement Policy, PMTA Guidance